drugset / Trial / NCT02351960

Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease

NCT02351960

Phase 4 Completed 296 enrolled Takeda
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effectiveness of symptom control in gastroesophageal reflux disease (GERD) participants following treatment with dexlansoprazole.

Timeline

Start
2015-03-19
Primary completion
2016-06-22
Completion
2016-07-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexlansoprazole Other / unclassified 30 mg Oral
Subject Dexlansoprazole Other / unclassified 60 mg Oral